June 9, 2016
Cambridge, MA

Solid Grows Therapeutic Pipeline with New Disease Modifying Therapy Candidate

Solid is committed to building a robust pipeline of candidates that target the multiple facets of Duchenne muscular dystrophy. It is with this goal in mind that we are excited to announce a new collaboration with Dr. Elizabeth McNally, M.D, Ph.D., of Northwestern University to develop a novel anti-fibrotic candidate with the potential to support muscle repair.

Muscular dystrophy is characterized by the replacement of muscle with non-functional fibrotic tissue, which is caused by continuous inflammation and muscle degeneration. The goal of this program is to target a known mediator of fibrosis, or TGF-b,  and inhibit its activity. We believe that this goal can be accomplished by modulating a protein known as the latent TGF-b binding protein 4 (LTBP4).

LTBP4 has been identified as a genetic modifier of Duchenne muscular dystrophy and has been associated with a delayed loss of ambulation. If successful, we believe that a therapy utilizing this novel pathway has the potential to reduce fibrosis in Duchenne muscular dystrophy patients and slow functional decline.

The LTBP4 candidate is currently in early discovery.  Solid is excited to work with Dr. McNally and her team to unlock the potential of LTBP4 and hopefully begin to move it through development

View Our Pipeline

Related news


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.


Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.


Solid Biosciences Community Update Q2 2016


Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.


Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”


Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular dystrophy.


More information about Solid?

Please subscribe to receive our latest news